Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST) is scheduled to announce its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to analyst estimates of $11.79 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded down $0.18 during midday trading on Tuesday, reaching $3.56. The company had a trading volume of 907,195 shares, compared to its average volume of 2,246,851. Aquestive Therapeutics has a 1-year low of $1.25 and a 1-year high of $6.23. The firm has a market cap of $260.95 million, a price-to-earnings ratio of -26.68 and a beta of 2.87. The company has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $2.84.

Insider Transactions at Aquestive Therapeutics

In other news, insider Alexander Mark Schobel sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the sale, the insider now owns 1,040,371 shares of the company’s stock, valued at approximately $5,399,525.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AQST has been the subject of a number of recent analyst reports. Piper Sandler began coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday. Raymond James started coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $7.00 price target for the company. Finally, JMP Securities raised their price target on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $8.00.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.